Found 324 clinical trials
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).
We at PGIMER have been practicing hypofractionated radiotherapy in breast cancer patients for the last 4 decades. Our standard doses have been 35Gy/15/3wks to the chest wall after mastectomy and 40Gy/16/3wks after breast conserving surgery (BCS).It is also a routine practice in the UK and in a few centers in …
- 0 views
- 01 Jul, 2021
- 1 location
PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study
The aim of this study is to examine if a shorter palliative radiotherapy fractionation scheme of 20 Gy / 4 F can reduce the early oesophageal toxicity compared to 30 Gy / 10 F in patients with lung cancer in performance status (PS) 0-2. Secondary aims are to examine the …
- 2 views
- 26 Jan, 2021
- 1 location
EGFR-targeted Therapy for Gastric Cancer
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
- 0 views
- 24 May, 2021
- 1 location
Matched Targeted Therapy For High-Risk Leukemias and MDS
specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the
- 0 views
- 12 Jun, 2021
- 15 locations
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant trastuzumab, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive human epidermal growth factor …
- 18 views
- 08 Sep, 2021
- 2 locations
Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions
This is an open-label and triple cohort study of the safety and efficacy of T27 and T512 to possibly treat cervical intraepithelial neoplasia(CIN).
- 1 views
- 05 Feb, 2021
- 1 location
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done
- 0 views
- 10 Oct, 2021
- 1 location
PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with …
- 38 views
- 11 May, 2021
- 1 location
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) or or displaced anaplastic lymphoma receptor tyrosine kinase (ALK) or ROS proto-oncogene 1 …
- 0 views
- 16 Feb, 2021
- 1 location
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas. In the pilot …
- 11 views
- 25 Jan, 2021
- 1 location